Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer
ConditionEndometrial Carcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age45+
SponsorMayo Clinic
About this trial
This study evaluates how women feel about using DNA from a vaginal fluid collection for early detection of endometrial cancer.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Self-identified Black individuals ≥ 45 years with an intact uterus
Assigned female sex at birth
Experience with abnormal uterine or post-menopausal bleeding (defined as vaginal bleeding between periods, heavy vaginal bleeding, vaginal bleeding after menopause, and/or red, brown, or pink colored vaginal discharge after menopause)
Willing to participate in a 45-minute virtual interview
Disqualifiers
Previous or current diagnosis of endometrial cancer
Trial population
Self-identified Black females 45 years or older with an intact uterus recruited through Mayo Clinic in Rochester
Trial design
Design model
Case-only
Time perspective
Cross-sectional
Treatments tested in this trial
Non-Interventional Study
Other interventionNon-interventional study
Treatment groups
25 Participants
are divided into 1 treatment groupGroup A: Observational1 intervention
Trial outcomes
Primary outcomes
1
Acceptability of vaginal fluid collection for a DNA-based early detection endometrial cancer test
Information collected during a 30-minute virtual interview using mostly open-ended questions. The interviews will be transcribed and reviewed by the study team to identity themes and create coding categories. Coding categories will be used to organize the data into subthemes. Results will be reported in aggregate. Aggregate results will be disseminated to participants if they elect to receive them.
Time frame
Baseline (30-minute virtual interview)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov